Last reviewed · How we verify
LP-300
At a glance
| Generic name | LP-300 |
|---|---|
| Also known as | Tavocept, BNP7787, Dimesna |
| Sponsor | Lantern Pharma Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (PHASE2)
- Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LP-300 CI brief — competitive landscape report
- LP-300 updates RSS · CI watch RSS
- Lantern Pharma Inc. portfolio CI